You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 5,616,488

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,616,488

Title:	IL-5 targeted ribozymes
Abstract:	Enzymatic RNA molecules which cleave IL-5 mRNA.
Inventor(s):	Sullivan; Sean (Alameda, CA), Draper; Kenneth G. (Boulder, CO), McSwiggen; James (Boulder, CO), Stinchcomb; Dan T. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/319,492
Patent Claims:	1. An enzymatic RNA molecule which specifically cleaves IL-5 mRNA. 2. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hammerhead motif. 3. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule is in a hairpin, hepatitis delta virus, group I intron, VS RNA or RNaseP RNA motif. 4. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises between 12 and 100 bases complementary to said mRNA. 5. The enzymatic RNA molecule of claim 1, wherein said enzymatic RNA molecule comprises between 14 and 24 bases complementary to said mRNA. 6. The enzymatic RNA molecule of claim 2, wherein said enzymatic RNA molecule specifically cleaves any of the sequences defined as SEQ. ID. NOs. 7-179. 7. The hairpin enzymatic RNA molecule of claim 3, wherein said enzymatic RNA molecule specifically cleaves any of the sequences defined as SEQ. ID. Nos. 703, 705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, or 751. 8. The enzymatic RNA molecule of claim 2, wherein said enzymatic RNA molecule consists of the sequences shown as SEQ. ID. Nos 180-353 or 528-701. 9. A mammalian cell including an enzymatic RNA molecule of any of claims 1-8 in vitro. 10. The cell of claim 9, wherein said cell is a human cell. 11. An expression vector including a nucleic acid encoding an enzymatic RNA molecule or multiple enzymatic RNA molecules of any of claims 1-8 in a manner which allows expression of that enzymatic RNA molecule(s) within a mammalian cell in vitro. 12. A mammalian cell including the expression vector of claim 11 in vitro. 13. The cell of claim 12, wherein said cell is a human cell. 14. The enzymatic RNA molecule of claim 3, wherein said hairpin comprises any of the sequences shown as SEQ. ID. NOs 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, or 750. 15. The enzymatic RNA molecule of claim 2, wherein said enzymatic RNA molecule comprises a stem II region, and wherein said stem II is greater than or equal to 2 base pairs long. 16. The enzymatic RNA molecule of claim 3, wherein said hairpin comprises a stem IV region, and wherein said stem IV is greater than or equal to 2 base pairs long. 17. The enzymatic RNA molecule of any of claims 1-8 and 14-16, wherein said enzymatic RNA molecule comprises at least one sugar modification. 18. The enzymatic RNA molecule of any of claims 1-8 and 14-16, wherein said enzymatic RNA molecule comprises at least one base modification. 19. The enzymatic RNA molecule of any of claims 1-8 and 14-16, wherein said enzymatic RNA molecule comprises at least one phosphate modification. 20. The enzymatic RNA molecule of any of claims 1-8 and 14-16, wherein said enzymatic RNA molecule comprises at least two sugar modifications, wherein one said modification is a 2'-O-methyl and the other said modification is a 2'-deoxy-2'-amino. 21. The enzymatic RNA molecule of any of claims 1-8 and 14-16, wherein said enzymatic RNA molecule comprises at least two sugar modifications, wherein one said modification is a 2'-O-methyl and the other said modification is a 2'-C-allyl. 22. The enzymatic RNA molecule of claim 19, wherein said phosphate modification is a phosphorothioate.

Details for Patent 5,616,488

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2014-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2014-04-01
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2014-04-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.